natgillin/translations-raw huggingface dataset:
• a history of neuroleptic malignant syndrome (a dangerous nervous system disorder usually caused by antipsychotic medicines) or rhabdomyolysis (breakdown of muscle fibres). 
• anamnezo nevroleptičnega malignega sindroma (nevarne bolezni živčnega sistema, ki jo običajno povzročijo antipsihotična zdravila) ali rabdomiolizo (razgradnjo mišičnega tkiva).
• severely reduced liver function; 
• hudo okvaro delovanja jeter;
Having all three substances in the same tablet can lower the number of tablets the patients have to take and help them stick to treatment. 
Ker ena tableta vsebuje vse tri učinkovine, je število tablet, ki jih mora bolnik zaužiti, manjše, kar jim pomaga držati se režima zdravljenja.
The full EPAR for Levodopa/Carbidopa/Entacapone Orion can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko poročilo o oceni zdravila (EPAR) za zdravilo Levodopa/Carbidopa/Entacapone Orion je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
The maximum daily dose of Levodopa/Carbidopa/Entacapone Orion is 10 tablets, except for the tablets containing 175 mg levodopa and 43.75 mg carbidopa, for which the maximum daily dose is eight tablets, and those containing 200 mg levodopa and 50 mg carbidopa, for which it is seven tablets. 
Največji dnevni odmerek zdravila Levodopa/Carbidopa/Entacapone Orion je 10 tablet, razen pri tabletah, ki vsebujejo 175 mg levodope in 43,75 mg karbidope, pri katerih je največji dnevni odmerek osem tablet, ter pri tistih, ki vsebujejo 200 mg levodope in 50 mg karbidope, ko je največji dnevni odmerek sedem tablet.
Serious side effects which have been reported much less often include gastrointestinal haemorrhage (bleeding in the gut) and angioedema (swelling under the skin of face or limbs). 
Resni neželeni učinki, o katerih so poročali zelo redko, vključujejo gastrointestinalno hemoragijo (krvavitve v črevesju) ter angiodem (podkožne otekline na obrazu in okončinah).
In patients with Parkinson's disease, the cells in the brain that produce dopamine (a substance used to transmit signals between nerve cells that help to control muscle movement) begin to die and the amount of dopamine in the brain decreases. 
Pri bolnikih s Parkinsonovo boleznijo pričnejo celice, ki proizvajajo dopamin (snov, ki prenaša signale med živčnimi celicami, ki pomagajo pri nadzoru mišičnih gibov), odmirati, zato se količina dopamina v možganih zmanjša.
• phaeochromocytoma (a tumour of the adrenal gland); 
• feokromocitom (tumor nadledvične žleze);
The CHMP decided that Levodopa/Carbidopa/Entacapone Orion's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Levodopa/Carbidopa/Entacapone Orion večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The European Commission granted a marketing authorisation valid throughout the European Union for Levodopa/Carbidopa/Entacapone Orion on 24 August 2011. 
Evropska komisija je dovoljenje za promet z zdravilom Levodopa/Carbidopa/Entacapone Orion, veljavno po vsej Evropski uniji, odobrila 24. avgusta 2011.
For more information about treatment with Levodopa/Carbidopa/Entacapone Orion, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Levodopa/Carbidopa/Entacapone Orion preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
Levodopa/Carbidopa/Entacapone Orion is used when these fluctuations cannot be treated with the standard combination alone. 
Zdravilo Levodopa/Carbidopa/Entacapone Orion se uporablja, kadar teh fluktuacij ni mogoče zdraviti samo s standardno kombinacijo.
The strength of Levodopa/Carbidopa/Entacapone Orion that the patient should use is based on the amount of levodopa they need to control their symptoms. 
Jakost zdravila Levodopa/Carbidopa/Entacapone Orion, ki naj jo bolnik jemlje, temelji na količini levodope, ki jo potrebuje za nadzor nad simptomi.
All of the active substances in Levodopa/Carbidopa/Entacapone Orion work to restore the levels of dopamine in the parts of the brain that control movement and co-ordination. 
Vse zdravilne učinkovine v zdravilu Levodopa/Carbidopa/Entacapone Orion delujejo tako, da ponovno vzpostavijo ravni dopamina v tistih delih možganov, ki nadzirajo gibe in koordinacijo.
The most common side effects with Levodopa/Carbidopa/Entacapone Orion (seen in more than 1 patient in 10) are dyskinesia (uncontrollable movements), muscle pain, diarrhoea and nausea (feeling sick) and harmless urine discoloration. 
Najpogostejši neželeni učinki zdravila Levodopa/Carbidopa/Entacapone Orion (opaženi pri več kot 1 bolniku od 10) so diskinezija (nekontrolirani gibi), bolečine v mišicah, diareja in slabost ter neškodljivo razbarvanje urina.
The studies showed that Levodopa/Carbidopa/Entacapone Orion is bioequivalent to the separate tablets. 
Študije so pokazale, da je zdravilo Levodopa/Carbidopa/Entacapone Orion biološko enakovredno ločenim tabletam.
Levodopa/Carbidopa/Entacapone Orion is used in patients who are being treated with a combination of levodopa and an inhibitor of dopa decarboxylase (two standard treatments for Parkinson's disease) but are having ‘fluctuations' towards the end of the period between two doses of their medication. 
Zdravilo Levodopa/Carbidopa/Entacapone Orion se uporablja pri bolnikih, ki se zdravijo s kombinacijo levodope in zaviralca dopa dekarboksilaze (dveh običajnih zdravil za Parkinsonovo bolezen), pri katerih pa se proti koncu obdobja med dvema odmerkoma zdravila pojavijo fluktuacije.
This is a summary of the European public assessment report (EPAR) for Levodopa/Carbidopa/Entacapone Orion. 
Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Levodopa/Carbidopa/Entacapone Orion.
Levodopa/Carbidopa/Entacapone Orion is used to treat adults with Parkinson's disease. 
Zdravilo Levodopa/Carbidopa/Entacapone Orion se uporablja za zdravljenje odraslih bolnikov s Parkinsonovo boleznijo.
Levodopa/Carbidopa/Entacapone Orion must not be used together with other medicines that belong to the group ‘monoamine oxidase inhibitors' (a type of antidepressant). 
Zdravilo Levodopa/Carbidopa/Entacapone Orion se ne sme uporabljati skupaj z drugimi zdravili, ki spadajo v skupino zaviralcev monoaminooksidaze (vrsta antidepresivov).
Levodopa/Carbidopa/Entacapone Orion must not be used in people who are hypersensitive (allergic) to levodopa, carbidopa, entacapone or any of the other ingredients. 
Zdravila Levodopa/Carbidopa/Entacapone Orion ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) levodopo, karbidopo, entakapon ali katero koli drugo sestavino zdravila.
The company used some of the data from Comtess/Comtan to support the use of Levodopa/Carbidopa/Entacapone Orion and presented data from the published literature for levodopa and carbidopa. 
Družba je v podporo uporabi zdravila Levodopa/Carbidopa/Entacapone Orion uporabila nekatere podatke o zdravilu Comtess/Comtan in predstavila podatke iz objavljene literature o levodopi in karbidopi.
Levodopa/Carbidopa/Entacapone Orion tablets should be taken whole, with or without food. 
Tablete zdravila Levodopa/Carbidopa/Entacapone Orion je treba vzeti cele,s hrano ali brez nje.
Each Levodopa/Carbidopa/Entacapone Orion tablet contains one complete dose of levodopa, in seven strengths, with corresponding amounts of carbidopa and entacapone to improve its effectiveness. 
Vsaka tableta zdravila Levodopa/Carbidopa/Entacapone Orion vsebuje en poln odmerek levodope v sedmih jakostih, za izboljšanje njene učinkovitosti pa še ustrezne količine karbidope in entakapona.
Levodopa/Carbidopa/Entacapone Orion is a medicine that contains three active substances: levodopa, carbidopa and entacapone. 
Levodopa/Carbidopa/Entacapone Orion je zdravilo, ki vsebuje tri zdravilne učinkovine: levodopo, karbidopo in entakapon.
• narrow-angle glaucoma (increased pressure within the eye); 
• glavkom z zaprtim zakotjem (povečan pritisk v očesu);
Levodopa/Carbidopa/Entacapone Orion must not be used in patients with: 
Zdravilo Levodopa/Carbidopa/Entacapone Orion se ne sme uporabljati pri bolnikih, ki imajo:
The company carried out ‘bioequivalence' studies to show that taking Levodopa/Carbidopa/Entacapone Orion produces the same levels of levodopa, carbidopa and entecapone in the blood as taking separate tablets containing entacapone and the combination of levodopa and carbidopa. 
Izvedla je tudi študije biološke enakovrednosti, da bi dokazala, da so ravni levodope, karbidope in entekapona v krvi pri jemanju zdravila Levodopa/Carbidopa/Entacapone Orion enake kot pri jemanju zdravilnih učinkovin v ločenih tabletah, od katerih ene vsebujejo entakapon, druge pa so kombinirane in vsebujejo levodopo in karbidopo.
For the full list of all side effects reported with Levodopa/Carbidopa/Entacapone Orion, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Levodopa/Carbidopa/Entacapone Orion, glejte navodilo za uporabo.
Other information about Levodopa/Carbidopa/Entacapone Orion 
Druge informacije o zdravilu Levodopa/Carbidopa/Entacapone Orion
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Levodopa/Carbidopa/Entacapone Orion. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Levodopa/Carbidopa/Entacapone Orion, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
They should be used with caution in patients with mild to moderately reduced liver function or severely reduced kidney function. 
Bolniki z blago do zmerno resno okvaro delovanja jeter ali hudo okvaro ledvic morajo tablete jemati previdno.
EPAR summary for the public levodopa/carbidopa/entacapone 
Povzetek EPAR za javnost levodopa/karbidopa/entakapon
What benefit has Levodopa/Carbidopa/Entacapone Orion shown during the studies? 
Kakšne koristi je zdravilo Levodopa/Carbidopa/Entacapone Orion izkazalo med študijami?
What is the risk associated with Levodopa/Carbidopa/Entacapone Orion? 
Kakšna tveganja so povezana z zdravilom Levodopa/Carbidopa/Entacapone Orion?
Why has Levodopa/Carbidopa/Entacapone Orion been approved? 
Zakaj je bilo zdravilo Levodopa/Carbidopa/Entacapone Orion odobreno?
What is Levodopa/Carbidopa/Entacapone Orion? 
Kaj je zdravilo Levodopa/Carbidopa/Entacapone Orion?
See the summary of product characteristics (also part of the EPAR) for full instructions on how patients should be switched to Levodopa/Carbidopa/Entacapone Orion, and on how the dose is adjusted during treatment. 
Za vsa navodila o tem, kako naj bolniki preidejo na jemanje zdravila Levodopa/Carbidopa/Entacapone Orion in kako je treba odmerek med zdravljenjem prilagajati, glejte povzetek glavnih značilnosti zdravila (ki je prav tako del EPAR).
How does Levodopa/Carbidopa/Entacapone Orion work? 
Kako zdravilo Levodopa/Carbidopa/Entacapone Orion deluje?
How has Levodopa/Carbidopa/Entacapone Orion been studied? 
Kako je bilo zdravilo Levodopa/Carbidopa/Entacapone Orion raziskano?
What is Levodopa/Carbidopa/Entacapone Orion used for? 
Za kaj se zdravilo Levodopa/Carbidopa/Entacapone Orion uporablja?
How is Levodopa/Carbidopa/Entacapone Orion used? 
Kako se zdravilo Levodopa/Carbidopa/Entacapone Orion uporablja?
Invented name Strength Pharmaceutical Form Route of administration 
Številka EU zaščiteno ime jakost farmacevtska oblika pot uporabe ovojnina vsebnost velikost pakiranja
What happens 
Kaj se bo dogajalo
All other bleeding events were nonserious. 
Vsi drugi dogodki krvavitve niso bili resni.
*Patients who have not received transfusions in the prior 60 days. 
*Bolniki, ki v predhodnih 60 dneh niso dobili transfuzije.
o The importance of annual check-ups. 
o Pomen letnih kontrolnih pregledov.
The selection of the treatment centres will be conducted in collaboration with national health authorities as appropriate. 
Centri za zdravljenje bodo izbrani v sodelovanju z nacionalnimi zdravstvenimi organi, kot je primerno.
***No patients are currently evaluable for these endpoints. 
***Za te izide trenutno ni bolnikov, ki bi jih bilo mogoče oceniti.
NR = Not reached. 
NR = ni dosežena (not reached).
This reduces or eliminates the need for blood transfusions. 
To zmanjša ali odpravi potrebo po transfuzijah krvi.
Do not thaw the product until it is ready to be used. 
Ne odtajajte izdelka, dokler ni pripravljen za uporabo.
This information is intended for doctors only. 
Te informacije so le za zdravnike.
All reactions resolved. 
Vse reakcije so izzvenele.
All patients remain alive at last follow-up. 
Vsi bolniki so bili pri zadnjem spremljanju še živi.
When 20 patients have been treated with 6 months follow-up 
Ko je bilo zdravljenih 20 bolnikov in po 6-mesečnem spremljanju
As this medicine will be given by a qualified doctor, they are responsible for the correct storage of the medicine before and during its use, as well as for its correct disposal. 
Ker bo zdravilo dal usposobljen zdravnik, je odgovoren za pravilno shranjevanje zdravila pred in med uporabo ter za njegovo pravilno odstranitev.
A chemotherapy medicine is given for 4 days in a hospital 
Zdravilo za kemoterapijo se daje 4 dni v bolnišnici
The minimum recommended dose is the same for adults and adolescents 12 years of age and older. 
Najmanjši priporočeni odmerek zdravila je enak za odrasle in mladostnike, stare 12 let in več.
Hb = Total Hb. WA Hb = Weighted average Hb. 
Hb = skupni Hb. WA Hb = tehtano povprečje Hb.
(See section 4.4 for guidance on platelet monitoring and management.) 
(Glejte poglavje 4.4. za smernice o spremljanju in obravnavi trombocitov.)
Frequencies are defined as: very common (≥1/10), and common (≥1/100 and <1/10). 
Pogostnosti so opredeljene kot: zelo pogosti (≥ 1/10), in pogosti (≥ 1/100 do < 1/10).
o Contact details where a health care professional can receive further information. 
o Kontaktni podatki, kjer lahko zdravstveni delavci dobijo dodatne informacije.
This will take place in a hospital and will take less than 30 minutes for each infusion bag. 
To bo potekalo v bolnišnici in bo trajalo manj kot 30 minut za vsako infuzijsko vrečko.
Options may include providing reproductive material for storage in a tissue bank to use at a later time. 
Možnosti lahko vključujejo shranitev reprodukcijskega materiala v banko tkiv za kasnejšo uporabo.
Risk of insertional oncogenesis 
Tveganje za insercijsko onkogenezo
^N represents the total number of patients evaluable for TI, defined as patients who have completed their parent study (i.e., 24 months of follow-up), or achieved TI, or will not achieve TI in their parent study. 
^N predstavlja skupno število bolnikov, ki so jih ovrednotili za TI, definirane kot bolnike, ki so zaključili svoje matične študije (tj. 24 mesecev spremljanja) ali so dosegli TI ali pa ne bodo dosegli TI v svoji matični študiji.
Date of first authorisation: 29 May 2019 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum prve odobritve: 29. maj 2019
NA = Not applicable. 
NA = ni smiselno (not applicable).
• bump your head or have a head injury 
• se udarite v glavo ali si poškodujete glavo;
Given the small patient population and size of cohorts, adverse reactions in the table below do not provide a complete perspective on the nature and frequency of these events. 
Glede na majhno populacijo bolnikov in velikost kohort neželeni učinki v spodnji preglednici ne zagotavljajo celotnega pogleda na naravo in pogostnost teh dogodkov.
Tell your doctor immediately if side effects become severe or serious. 
Takoj obvestite zdravnika, če neželeni učinki postanejo hudi ali resni.
• other pain 
• druge bolečine
Because of this defect, people with TDT are anaemic and need frequent blood transfusions to survive. 
Zaradi te okvare so ljudje s TDT anemični in za preživetje potrebujejo pogoste transfuzije krvi.
Study Total number (adolescents) 
Skupno število (mladostniki)
Common (≥1% - <10%) 
Pogosti (≥ 1% - < 10 %)
Patients should be made aware of the risk of bleeding events that are not easily identifiable, such as internal bleeding. 
Bolnike je treba opozoriti na tveganje dogodkov krvavitev, ki jih ni enostavno prepoznati, na primer notranje krvavitve.
Name (Last, First): 
Ime (priimek, ime):
This leaflet was last revised in <{MM/YYYY}> 
Navodilo je bilo nazadnje revidirano dne{MM/LLLL}.
Effects on male and female fertility have not been evaluated in animal studies. 
Vplivi na plodnost pri moških in ženskah niso bili ocenjeni v študijah na živalih.
Busulfan dose adjustments were made as needed based on pharmacokinetic monitoring. 
Odmerek busulfana so prilagodili, kot je bilo potrebno na podlagi farmakokinetičnega spremljanja.
You must get medical attention if you: 
Poiščite zdravniško pomoč, če:
o The potential risk of loss of response to gene therapy may lead to loss of transfusion independence or increase transfusion needs for patients who did not reach transfusionindependence. 
o Možno tveganje izgube odgovora na gensko zdravljenje lahko vodi v izgubo neodvisnosti od transfuzij ali povečano potrebo po transfuziji pri bolnikih, ki niso dosegli neodvisnosti od transfuzije.
- Read the Patient Alert Card carefully and follow the instructions on it. 
- Natančno preberite opozorilno kartico bolnika in upoštevajte navodila, ki so na njej.
Your doctor will advise you if and when you should start taking these medicines after Zynteglo infusion. 
Zdravnik vam bo svetoval, če in kdaj začeti jemati ta zdravila po infuziji zdravila Zynteglo.
Interim results: - at each annual renewal - Dec. 2024 - Dec. 2034 
Vmesni rezultati: - ob vsakoletnem podaljšanju - Dec. 2024 - Dec. 2034
This information is provided in the Patient Alert Card which should be given to the patient after treatment. 
Te informacije se navedejo v opozorilni kartici bolnika, ki jo je treba dati bolniku po zdravljenju.
• dizziness, or sensation of feeling off balance or like the room is spinning 
• vrtoglavica ali občutek neravnotežja, kot da se soba vrti
If a third day of collection was needed, plerixafor and G-CSF dosing was extended to Day 6. 
Če je bil potreben tretji dan odvzema, je bil odmerek pleriksaforja in G-CSF podaljšan do 6. dne.
You should carry the Patient Alert Card with you at all times and show it to your doctor or nurse when you see them or if you are admitted to the hospital. 
Opozorilno kartico bolnika morate imeti vedno pri sebi in jo pokazati zdravniku ali medicinski sestri, ko ju vidite ali ob morebitnem sprejemu v bolnišnico.
Very Common (≥10%) 
Zelo pogosti (≥ 10 %)
• increase in female hormones 
• povečanje koncentracije ženskih hormonov
Patients are expected to enrol in a registry and will be followed long term in the registry in order to better understand the long-term safety and efficacy of Zynteglo. 
Pričakuje se, da se bolniki vpišejo v register in da bodo dolgoročno spremljani v registru, da bi bolje razumeli dolgoročno varnost in učinkovitost zdravila Zynteglo.
They usually happen within the first few days and several weeks after receiving chemotherapy medicine, but can also develop much later. 
Običajno se pojavijo v prvih dneh in nekaj tednih po prejemu zdravila za kemoterapijo, vendar se lahko razvijejo tudi veliko pozneje.
Serological testing 
Serološko testiranje
o Signs and symptoms of bleeding and the need to contact the physician if any signs of unusual or prolonged bleeding or any other relevant signs are present. 
o Znaki in simptomi krvavitev in potreba po obveščanju zdravnika, če so prisotni znaki nenavadne ali podaljšane krvavitve ali drugi pomembni znaki.
Also contains Cryostor CS5 and sodium chloride. 
Vsebuje tudi Cryostor CS5 in natrijev klorid.
Patients seropositive for human immunodeficiency virus (HIV) or human T-lymphotropic virus (HTLV) 
Bolniki, seropozitivni za virus humane imunske pomanjkljivosti (HIV) ali humani T-limfotropni virus (HTLV)
People with this condition cannot make enough haemoglobin, a protein in the blood that carries oxygen. 
Osebe s to boleznijo ne morejo tvoriti dovolj hemoglobina, beljakovine v krvi, ki prenaša kisik.
• low number of immature (not fully developed) red blood cells 
• nizko število nezrelih (nepopolno razvitih) rdečih krvnih celic
See section 2, Sodium content. 
Glejte poglavje 2, Vsebnost natrija.
• infections which may make you feel warm, chilly, or sweaty 
• okužbe, zaradi katerih vam je vroče, hladno ali se znojite
Events were mild and included abdominal pain, hot flush, dyspnoea, and non-cardiac chest pain in 9.5%, 2.4%, 2.4%, and 2.4% of patients, respectively. 
Dogodki so bili blagi in so vključevali bolečine v trebuhu, vročinske oblive, dispnejo in bolečine v prsnem košu, ki niso povezane s srcem pri 9,5 %, 2,4 %, 2,4 % oz. 2,4 % bolnikov.
• flu like illness 
• gripi podobna bolezen
o Details on reporting of adverse effects. 
o Podrobnosti o poročanju neželenih učinkov.
To recover and be monitored until your doctor is satisfied that it is safe for you to leave the hospital. 
Da si boste opomogli in vas bodo lahko spremljali, dokler vaš zdravnik ne bo presodil, da lahko varno zapustite bolnišnico.
• positive test for Apergillus (lung disease caused by fungus) 
• pozitiven test za apergilus (bolezen pljuč, ki jo povzroči glivica)
o Enrolment in the drug product Registry. 
o Vključitev v register zdravila.
Your doctor will tell you when your platelet count has recovered to normal levels. 
Zdravnik vam bo povedal, ko se bo število trombocitov vrnilo na normalno raven.
Patients should be monitored for thrombocytopenia and bleeding according to standard guidelines. 
Bolnike je treba spremljati zaradi trombocitopenije in krvavitve v skladu s standardnimi smernicami.
The safety of Zynteglo was evaluated in 42 patients with TDT. 
Varnost zdravila Zynteglo je bilo ocenjena pri 42 bolnikih s TDT.
For women, this may be eggs (oocytes) or ovarian tissue. 
Pri ženskah so to lahko jajčea (oociti) ali tkivo jajčnikov.
During the long-term follow-up, your doctor will monitor you for any signs of leukaemia or lymphoma. 
Med dolgoročnim spremljanjem vas bo zdravnik spremljal glede znakov levkemije ali limfoma.
Risks associated with TDT and iron overload 
Tveganja, povezana s TDT in prenasičenostjo z železom
• low level of red and white blood cells, sometimes with a fever 
• nizka raven rdečih in belih krvnih celic, včasih s povišano telesno temperaturo
- The other ingredients are a solution used to preserve frozen cells and sodium chloride. 
- Druge sestavine so raztopina, ki se uporablja za ohranjanje zamrznjenih celic, in natrijev klorid.
A patient may have multiple infusion bags. 
Bolnik ima lahko več infuzijskih vrečk.
Patients should be assessed for renal impairment defined as creatinine clearance ≤70 mL/min/1.73 m2 to ensure HSC transplantation is appropriate. 
Bolnike je treba oceniti za okvaro ledvic, opredeljeno kot očistek kreatinina ≤ 70 ml/min/1,73 m2, da se potrdi primernost presaditve HSC.
Interim report: at each annual renewal 
Vmesno poročilo: ob vsakem letnem podaljšanju
Frozen: 1 year at ≤-140°C. 
Zamrznjeno: 1 leto pri ≤ -140 °C.
Pharmacotherapeutic group: Other haematological agents, ATC code: not yet assigned Mechanism of action 
Farmakoterapevtska skupina: druge hematološke učinkovine, oznaka ATC: še ni bila dodeljena
After treatment with Zynteglo, you will be asked to enrol in a registry for at least 15 years in order to better understand the long-term effects of Zynteglo. 
Po zdravljenju z zdravilom Zynteglo vas bodo prosili za vključitev v register za vsaj 15 let za boljše razumevanje dolgoročnih učinkov zdravila Zynteglo.
Your children are still at risk of inheriting your original beta-globin gene. 
Pri vaših otrocih še vedno obstaja tveganje, da bodo podedovali vaš osnovni gen za beta-globin.